West Pharmaceutical Services, Inc. filings document the regulatory record of a Pennsylvania operating company that supplies injectable drug containment, delivery and contract-manufacturing services. Its Form 8-K reports commonly furnish quarterly and full-year operating results, financial presentation materials and Regulation FD disclosures tied to earnings releases.
West's proxy and annual meeting filings cover board elections, executive compensation, advisory votes and shareholder voting results for its common stock. Other current reports record executive-transition matters and related governance disclosures, while exhibit filings provide the formal press releases, presentations and Inline XBRL cover-page data attached to those events.
West Pharmaceutical Services, Inc. (WST) – Form 4 insider filing
On 30 June 2025, director Janet Brutschea Haugen reported an equity-based compensation transaction:
- 58 Phantom Stock Units (deferred share equivalents) were acquired (Code A) at an indicated reference price of $218.80 per unit.
- Following the award, Haugen now holds 114.06 phantom units and 1,318.4 common shares, all in direct ownership.
Phantom units convert to common stock only after the director leaves the board, indicating a long-term alignment of interests rather than an immediate open-market purchase or sale. No common-stock transactions were reported, and the filing does not reference any Rule 10b5-1 trading plan.